牛牛AI助理已提取核心訊息
Shattuck Labs, Inc.'s Chief Medical Officer, Arundathy N. Pandite, completed a sale of company stock on January 30, 2024. The transaction involved the disposal of 2,920 shares of common stock at a price of $9.99 per share. Following the sale, Pandite's direct holdings in Shattuck Labs amount to 216,360 shares. The sale, which was conducted under transaction code 'F', indicating a payment of exercise price or tax liability by delivering or withholding securities, resulted in a total market value of $29,170.80.
Shattuck Labs, Inc.'s Chief Medical Officer, Arundathy N. Pandite, completed a sale of company stock on January 30, 2024. The transaction involved the disposal of 2,920 shares of common stock at a price of $9.99 per share. Following the sale, Pandite's direct holdings in Shattuck Labs amount to 216,360 shares. The sale, which was conducted under transaction code 'F', indicating a payment of exercise price or tax liability by delivering or withholding securities, resulted in a total market value of $29,170.80.
Shattuck Labs, Inc. '的首席醫療官阿倫達西·潘迪特於2024年1月30日完成了公司股票的出售。該交易涉及以每股9.99美元的價格出售2920股普通股。出售後，潘迪特在Shattuck Labs的直接持股量爲216,360股。此次出售是在交易代碼 “F” 下進行的，表示通過交付或預扣證券支付了行使價或應納稅額，總市值爲29,170.80美元。
Shattuck Labs, Inc. '的首席醫療官阿倫達西·潘迪特於2024年1月30日完成了公司股票的出售。該交易涉及以每股9.99美元的價格出售2920股普通股。出售後，潘迪特在Shattuck Labs的直接持股量爲216,360股。此次出售是在交易代碼 “F” 下進行的，表示通過交付或預扣證券支付了行使價或應納稅額，總市值爲29,170.80美元。
有用
沒用